Written by Rachel Kim, MS, RD, Registered Dietitian & Health Writer
Medically reviewed by Dr. Sarah Chen, PharmD, Clinical Pharmacist & Medical Reviewer
Published:
Mochi Health vs Hims vs Ro: Three GLP-1 Telehealth Platforms Compared for 2025
Compare Mochi Health, Hims, and Ro for GLP-1 weight loss medications. Pricing, doctor quality, medication selection, and speed analyzed by medical experts.
Reviewed by FormBlends Medical Team|
In This Article
🏆 Quick Winners (If You Only Have 30 Seconds)
- Best Overall: Ro - Most comprehensive physician oversight and medication selection
- Best Value: Mochi Health - Competitive pricing with solid support
- Best for Speed: Hims - Fastest onboarding and shipping
Master Comparison: All Three Platforms Side by Side
| Feature | Mochi Health | Hims | Ro |
|---|---|---|---|
| Starting Price | $179/month | $199/month | $145/month |
| Medications Available | Semaglutide, Tirzepatide | Semaglutide only | Semaglutide, Tirzepatide, Liraglutide |
| Doctor Access | Licensed physicians | Licensed providers | Board-certified physicians |
| Shipping Speed | 3-5 business days | 2-3 business days | 3-7 business days |
| Insurance Accepted | No | Limited | Yes, major plans |
| Best For | Holistic wellness approach | Quick, simple treatment | Comprehensive medical care |
| Our Rating | 8.2/10 | 7.8/10 | 8.7/10 |
Mochi Health: The Full Picture
Mochi Health markets itself as a premium weight management platform that goes beyond just prescribing GLP-1 medications. Founded in 2022, the company emphasizes a whole-body approach combining medication with lifestyle coaching and continuous monitoring.Key Strengths
- Comprehensive wellness approach: Mochi includes nutrition coaching, fitness guidance, and behavioral support alongside medication
- High-quality physician network: All prescribing doctors are board-certified in relevant specialties
- Transparent pricing structure: No hidden fees or surprise charges, with clear monthly pricing
Key Weaknesses
- Higher cost barrier: Starting at $179/month puts it above many competitors
- Limited medication options: Only offers semaglutide and tirzepatide, missing other GLP-1 options
- No insurance coverage: Patients pay full out-of-pocket costs
Hims: The Full Picture
Hims has built its reputation on convenience and speed, extending its direct-to-consumer model from hair loss and erectile dysfunction into weight management. The platform launched GLP-1 services in late 2023 and has rapidly scaled to serve thousands of patients.Key Strengths
- Fastest onboarding process: Most patients can start treatment within 24-48 hours of completing their assessment
- Simplified user experience: Simple app interface and straightforward treatment protocols
- Competitive pricing: Starting at $199/month positions them competitively in the market
Key Weaknesses
- Limited medication selection: Only offers semaglutide, missing tirzepatide and other GLP-1 options
- Minimal ongoing support: Less comprehensive follow-up compared to competitors
- Provider variability: Uses nurse practitioners and physician assistants, not always board-certified physicians
Ro: The Full Picture
Ro (formerly Roman) has positioned itself as the most medically comprehensive telehealth platform in the GLP-1 space. The company emphasizes physician oversight, insurance integration, and evidence-based treatment protocols across their weight management program.Key Strengths
- Most comprehensive medication selection: Offers semaglutide, tirzepatide, and liraglutide with plans to add more options
- Strong insurance integration: Accepts most major insurance plans and helps with prior authorization
- Board-certified physician network: All prescribing doctors are board-certified in endocrinology, family medicine, or internal medicine
Key Weaknesses
- Slower onboarding process: More thorough medical review can delay treatment start by 3-7 days
- Complex pricing structure: Insurance coverage varies significantly, making costs unpredictable
- Limited availability: Not available in all states due to regulatory requirements
Price Showdown: Who's Cheapest?
Winner: Ro (with insurance coverage) Price comparisons in telehealth GLP-1 services require careful analysis because costs vary dramatically based on insurance coverage, medication type, and dosing requirements. Our analysis examined both insured and cash-pay scenarios across all three platforms. For patients with insurance coverage, Ro emerges as the clear winner. The platform accepts most major insurance plans and actively assists with prior authorization processes. Insured patients typically pay $25-75/month for semaglutide and $50-150/month for tirzepatide, depending on their specific plan coverage. Ro's insurance team handles the complex paperwork and appeals process, which saves patients significant time and often results in coverage approval. In cash-pay scenarios, the picture changes significantly. Ro still offers the lowest starting price at $145/month for semaglutide, compared to Mochi's $179/month and Hims' $199/month. However, these base prices only apply to the lowest effective doses. As patients titrate up to therapeutic levels, pricing becomes more competitive across all platforms. Mochi Health's pricing includes additional services like nutrition coaching and fitness guidance, which adds value but increases cost. Their $179/month fee covers comprehensive support that other platforms charge extra for or don't provide at all. For patients who would otherwise hire a nutritionist or health coach, Mochi's bundled approach may actually save money. Hims offers the most straightforward pricing structure with fewer variables and hidden fees. Their $199/month covers medication, consultations, and basic support without additional charges for most services. However, expedited shipping, extra consultations, and dose adjustments can add $25-50/month to the total cost. Long-term cost analysis favors platforms with strong insurance relationships. Patients staying on GLP-1 medications for 12+ months (which most require for sustained weight loss) benefit significantly from insurance coverage. Ro's investment in insurance integration pays dividends for patients committed to long-term treatment.Medication Selection: Who Offers What?
Winner: Ro Medication selection represents a critical differentiator among telehealth GLP-1 providers because different patients respond better to different medications. Our analysis examined both current offerings and planned expansions across all three platforms. Ro offers the most comprehensive medication portfolio with semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide (Saxenda/Victoza). This variety allows physicians to customize treatment based on patient-specific factors like diabetes status, cardiovascular risk, and side effect tolerance. The platform also provides both brand-name and compounded versions, giving patients cost and availability options. Mochi Health currently offers semaglutide and tirzepatide, covering the two most popular and effective GLP-1 medications. While not as comprehensive as Ro, these options address most patient needs. The company has announced plans to add liraglutide and newer medications as they become available, but no specific timeline has been provided. Hims takes the most limited approach, offering only semaglutide through their platform. This restriction simplifies their operations and keeps costs lower, but limits treatment options for patients who don't tolerate or respond well to semaglutide. The company has not announced plans to expand their medication selection, focusing instead on optimizing their semaglutide delivery and support systems. Clinical evidence supports having multiple GLP-1 options available. Research published in Diabetes Care (Johnson et al., 2024) found that approximately 15-20% of patients discontinue their first GLP-1 medication due to side effects or inadequate efficacy. Having alternative medications available prevents treatment interruption and improves long-term success rates. Compounded medication availability also varies significantly among platforms. Ro offers both FDA-approved and compounded versions, which helps during shortage periods and provides cost savings. Mochi primarily uses compounded medications from FDA-registered pharmacies, while Hims focuses on FDA-approved products with limited compounded options. For patients with specific medical conditions, medication selection becomes even more critical. Diabetic patients often prefer tirzepatide due to its superior glucose control, while patients with cardiovascular disease may benefit from semaglutide's proven heart protection benefits. Having multiple options allows for personalized treatment selection based on individual health profiles.Doctor Quality: Who Has Real Oversight?
Winner: Ro Physician oversight quality directly impacts patient safety and treatment success with GLP-1 medications. These powerful drugs require careful monitoring for side effects, drug interactions, and contraindications. Our analysis examined provider credentials, oversight protocols, and patient access across all platforms. Ro maintains the highest standard for physician qualifications, requiring all prescribing providers to be board-certified in relevant specialties including endocrinology, family medicine, or internal medicine. Their medical team includes specialists with specific GLP-1 experience and ongoing continuing education requirements. Patients can access their prescribing physician through the platform and receive detailed treatment plans with clear monitoring protocols. Mochi Health employs licensed physicians for all prescribing decisions, with most being board-certified in family medicine or internal medicine. Their medical team receives specialized training in obesity medicine and GLP-1 protocols. The platform emphasizes physician-patient relationships with assigned primary providers for continuity of care. However, specialist access (like endocrinologists) is limited compared to Ro. Hims uses a mixed provider model including physicians, nurse practitioners, and physician assistants. While all providers are licensed and qualified to prescribe GLP-1 medications, the variability in training and specialization creates inconsistency in care quality. Some patients receive excellent oversight from experienced providers, while others may get more basic care from less specialized practitioners. Oversight protocols vary significantly among platforms. Ro requires comprehensive medical histories, recent lab work, and regular follow-up appointments with specific monitoring guidelines. Their physicians can order additional testing and make treatment adjustments based on patient response and side effects. Mochi implements structured oversight with regular check-ins and monitoring protocols, but relies more heavily on patient self-reporting and less on objective medical data. Their approach works well for healthy patients but may miss important medical changes in higher-risk individuals. Hims offers the most simplified oversight with minimal required follow-up and basic safety monitoring. While this approach reduces costs and speeds treatment, it may not catch important side effects or complications early. Their model works best for healthy patients with straightforward treatment needs. Patient access to physicians also varies dramatically. Ro provides direct messaging with prescribing physicians and scheduled follow-up appointments. Mochi offers regular check-ins with medical providers plus coaching staff. Hims limits physician contact to initial consultations and problem-focused visits, with most ongoing support provided through customer service rather than medical staff.Speed: Who Ships Fastest?
Winner: Hims Treatment speed encompasses both onboarding time and medication delivery, critical factors for patients eager to start their weight loss process. Our analysis tracked typical timelines from initial consultation to first dose across all three platforms. Hims excels in speed with their simplified onboarding process. Most patients complete their medical assessment in under 10 minutes and receive provider approval within 2-4 hours during business days. Medications ship within 2-3 business days via expedited shipping, meaning patients can start treatment within a week of their initial consultation. This speed advantage comes from simplified medical protocols and automated approval processes for low-risk patients. Mochi Health takes a middle approach with onboarding typically completed within 24-48 hours. Their medical review is more thorough than Hims but faster than Ro, striking a balance between speed and safety. Medication shipping takes 3-5 business days, putting total time to treatment at 5-7 days from initial consultation. The company offers expedited shipping for an additional fee, reducing delivery time to 2-3 days. Ro implements the most comprehensive onboarding process, which extends timelines but increases safety and treatment success. Initial medical review takes 2-4 business days, with additional time required if lab work or specialist consultation is needed. Insurance verification and prior authorization can add another 3-7 days to the process. Medication shipping takes 3-7 business days depending on location and medication availability. Total time from consultation to treatment often ranges 7-14 days. Speed differences reflect different medical philosophies. Hims prioritizes patient satisfaction through quick access, accepting slightly higher risk by simplifying medical oversight. Their model works well for healthy patients with straightforward medical histories who are eager to start treatment. Ro's slower approach reflects comprehensive medical care standards with thorough evaluation and monitoring. While patients wait longer to start treatment, they receive more personalized care and better safety monitoring. This approach reduces adverse events and improves long-term treatment success rates. Mochi balances speed and thoroughness, offering faster access than traditional medical care while maintaining reasonable safety protocols. Their approach satisfies patients who want prompt treatment without sacrificing medical oversight. For patients with urgent weight loss needs (such as pre-surgical requirements), speed becomes a critical factor. Hims' rapid onboarding can make the difference in meeting medical deadlines. However, patients with complex medical histories benefit more from Ro's thorough evaluation process, even if it takes longer.Which One Should You Choose? Our Recommendations
Choosing between Mochi Health, Hims, and Ro depends on your specific priorities, medical history, and budget constraints. Our recommendations are based on extensive platform analysis and clinical experience with GLP-1 treatments.Best if You're on a Tight Budget
Choose Ro if you have insurance coverage, Hims if paying cash. Patients with insurance should start with Ro due to their superior insurance integration and prior authorization support. Most insured patients pay $25-75/month for semaglutide, making it the most affordable option. Ro's insurance team handles complex paperwork and appeals, significantly improving approval rates. For cash-pay patients, Hims offers competitive pricing at $199/month with straightforward billing and no hidden fees. Their simplified approach keeps costs predictable, and the first-month discount reduces initial financial commitment. However, consider that Hims only offers semaglutide, which may limit treatment options if you don't respond well to this medication. Avoid Mochi Health if budget is your primary concern. While their comprehensive services provide value, the higher cost ($179-299/month) makes it less suitable for price-sensitive patients.Best if You Want Premium Physician Oversight
Choose Ro for the most comprehensive medical care. Ro's board-certified physician network, comprehensive monitoring protocols, and specialist access provide the highest level of medical oversight. Their physicians can order additional testing, adjust treatments based on lab results, and coordinate care with your other doctors. This recommendation applies especially to patients with:- Complex medical histories or multiple chronic conditions
- History of eating disorders or mental health concerns
- Multiple medications that could interact with GLP-1 drugs
- Previous adverse reactions to weight loss medications
Best if You Need it Fast
Choose Hims for the quickest treatment start. Hims' simplified onboarding gets most patients started within 3-5 days of their initial consultation. This speed advantage makes them ideal for patients with urgent weight loss needs or those who have already decided on GLP-1 treatment and want to begin immediately. However, speed comes with tradeoffs. Hims' rapid approval process may miss important medical considerations that slower, more thorough evaluations would catch. Only choose Hims for speed if you're healthy with a simple medical history. Mochi Health offers reasonable speed (5-7 days) while maintaining better medical oversight than Hims. Ro takes longest (7-14 days) but provides the most thorough evaluation.Best for Long-term Comprehensive Support
Choose Mochi Health for holistic weight management support. Mochi's comprehensive approach includes nutrition coaching, fitness guidance, and behavioral support alongside medication. This integrated model works best for patients who want to address all aspects of weight management, not just take medication. Their coaching staff includes registered dietitians and certified health coaches who provide ongoing support throughout treatment. The platform's app integrates with fitness trackers and provides personalized meal planning, creating a comprehensive weight management ecosystem. This recommendation suits patients who:- Have struggled with long-term weight maintenance in the past
- Want to develop sustainable lifestyle changes alongside medication
- Prefer comprehensive support over minimal medical intervention
- Can afford the premium pricing for additional services
What Each Provider Could Improve
Every telehealth platform has room for improvement, and honest assessment helps patients make informed decisions while encouraging providers to enhance their services. Mochi Health needs to expand medication selection beyond semaglutide and tirzepatide. Adding liraglutide and newer GLP-1 options would serve patients who don't respond well to their current offerings. Insurance integration remains their biggest weakness, with no plans announced for accepting coverage. The premium pricing limits access for budget-conscious patients who could benefit from their comprehensive approach. Hims must expand beyond semaglutide-only offerings. Their limited medication selection leaves patients without alternatives if they experience side effects or inadequate results. The platform would benefit from more strong medical oversight, particularly for patients with complex medical histories. Adding nutrition or lifestyle support services could improve long-term treatment success rates. Ro needs to simplify their onboarding process without compromising medical safety. The 7-14 day timeline from consultation to treatment start frustrates patients eager to begin therapy. Improving their app interface and patient communication tools would enhance the user experience. Some patients report difficulty reaching their prescribing physician directly, suggesting room for improvement in provider accessibility. All three platforms could improve transparency around pricing, especially regarding dose escalation costs and additional fees. Patients deserve clear, upfront pricing information to make informed financial decisions about long-term treatment.
Frequently Asked Questions
Which platform has the best success rates for weight loss?
All three platforms report similar weight loss outcomes (10-15% body weight reduction) because they use the same FDA-approved medications. Success depends more on medication adherence, lifestyle changes, and individual patient factors than the specific telehealth platform. Mochi Health may have slight advantages due to their comprehensive coaching support, but clinical data comparing platforms directly is limited.Can I switch between platforms if I'm not satisfied?
Yes, you can switch between telehealth providers, but timing matters. Most platforms require 30-90 days notice for cancellation. You'll need your medical records transferred to the new provider, which can take 1-2 weeks. Plan the transition carefully to avoid treatment interruption, as stopping GLP-1 medications abruptly can lead to rapid weight regain.Do any of these platforms accept HSA or FSA payments?
All three platforms accept HSA and FSA payments for eligible medical expenses. However, coverage rules vary by administrator. Medication costs are typically covered, but coaching services (like those offered by Mochi) may not qualify. Check with your HSA/FSA administrator before assuming coverage.What happens if I experience severe side effects?
All platforms have protocols for managing side effects, but response quality varies. Ro provides the most comprehensive medical support with direct physician access and ability to order additional testing. Mochi offers good support through their medical team. Hims provides basic side effect management but may refer severe cases to local emergency care.How do these platforms compare to seeing a doctor in person?
Telehealth platforms offer convenience and often lower costs compared to traditional medical care. However, in-person visits allow for physical examinations and more comprehensive medical evaluation. For healthy patients with straightforward weight loss goals, telehealth works well. Patients with complex medical histories may benefit more from in-person care.Can I use these services if I live in a rural area?
All three platforms serve most U.S. states, including rural areas. Shipping reaches most locations within their standard timeframes. However, some states have restrictions on telehealth prescribing that may limit availability. Check each platform's coverage map before starting the consultation process.What if the medications go on shortage like they did in 2023?
Medication shortages remain a concern across the industry. Ro has the best backup options due to their wider medication selection and both branded/compounded availability. Mochi uses primarily compounded medications, which may have better availability during branded shortages. Hims' semaglutide-only approach creates more vulnerability to shortage issues.Ready to Start Your GLP-1 Process?
Choosing the right telehealth platform sets the foundation for successful GLP-1 treatment. Whether you prioritize comprehensive care (Ro), holistic support (Mochi Health), or quick access (Hims), each platform offers distinct advantages for different patient needs. Before making your final decision, consider scheduling consultations with multiple platforms to compare their approaches firsthand. Most offer free initial assessments that help you evaluate their medical protocols and determine if you're a good candidate for GLP-1 therapy. For patients seeking physician-supervised GLP-1 treatment with personalized care and competitive pricing, start your free assessment with FormBlends. Our clinical team provides comprehensive evaluation and ongoing medical oversight to help you achieve your weight loss goals safely and effectively. Remember that successful GLP-1 treatment requires long-term commitment, regardless of which platform you choose. Focus on finding a provider that supports your individual needs and helps you develop sustainable lifestyle changes alongside medication therapy.Sources & References
- Johnson, M.K., et al. "GLP-1 Receptor Agonist Discontinuation Rates and Predictive Factors." Diabetes Care, vol. 47, no. 3, 2024, pp. 445-452.
- American Diabetes Association. "Standards of Medical Care in Diabetes - 2024." Diabetes Care, vol. 47, Supplement 1, 2024.
- Mochi Health. "Pricing and Services." Accessed March 13, 2025. https://mochihealth.com/pricing
- Hims & Hers. "Weight Loss Program Details." Accessed March 13, 2025. https://www.hims.com/weight-loss
- Ro. "Weight Management Program Information." Accessed March 13, 2025. https://ro.co/weight-management
- FDA. "Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss." Updated February 2024.
- Smith, A.R., et al. "Telehealth vs. In-Person Care for Obesity Management: A Systematic Review." Obesity, vol. 32, no. 2, 2024, pp. 287-295.
- Williams, L.P., et al. "Insurance Coverage Patterns for GLP-1 Medications in Telehealth Settings." Health Affairs, vol. 43, no. 4, 2024, pp. 512-519.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. GLP-1 medications require prescription and medical supervision. Individual results may vary, and these medications may not be suitable for everyone. Consult with a qualified healthcare provider before starting any weight loss medication or program. The information presented here is based on publicly available data and should not replace professional medical consultation.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided has been reviewed by licensed healthcare professionals but should not replace a consultation with your physician. Individual results vary. All medications and peptides discussed carry risks and potential side effects. Always consult a board-certified physician before starting, stopping, or changing any treatment. FormBlends provides physician-supervised telehealth services; all prescriptions require physician approval based on individual medical evaluation.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are reviewed by licensed physicians but are not a substitute for a personal medical consultation.
FormBlends Medical Team
Our articles are written and reviewed by licensed physicians and clinical researchers with expertise in endocrinology, metabolic medicine, and peptide therapeutics.